Ads
related to: zofran odt dose for nausea symptoms in adults
Search results
Results From The WOW.Com Content Network
Ondansetron, sold under the brand name Zofran among others, is a medication used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, migraines, or surgery. [8] It is also effective for treating gastroenteritis. [9] [10] It can be given orally (by mouth), intramuscularly (injection into a muscle), or intravenously ...
An orally disintegrating tablet or orally dissolving tablet (ODT) is a drug dosage form available for a limited range of over-the-counter (OTC) and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.
“Zofran is an anti-nausea medication,” says Qing, and it’s typically used preventatively. Zofran is an antiemetic that works by blocking the chemical that causes nausea and vomiting, per the ...
Promethazine (Pentazine, Phenergan, Promacot) can be administered via a rectal suppository, intravenous injection, oral tablet or oral suspension for adults and children over 2 years of age. Hydroxyzine (Vistaril) Cannabinoids are used in patients with cachexia, cytotoxic nausea, and vomiting, or who are unresponsive to other agents. These may ...
These drugs block one or more of the nerve signals that cause nausea and vomiting. During the first 24 hours after chemotherapy, the most effective approach appears to be blocking the 5-HT 3 nerve signal. [10] Approved 5-HT 3 inhibitors include dolasetron (Anzemet), granisetron (Kytril, Sancuso), and ondansetron (Zofran). Their antiemetic ...
Benefits are greater if used before the onset of symptoms or shortly after symptoms begin. [2] Side effects, however, may limit the use of medications. [3] A number of medications used for nausea such as ondansetron and metoclopramide are not effective in motion sickness. [3] [2]
5-HT 3 antagonists are most effective in the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV), especially that caused by highly emetogenic drugs such as cisplatin; when used for this purpose, they may be given alone or, more frequently, with a glucocorticoid, usually dexamethasone.
The technology's first commercial application was in August, 1993, when a new dosage form of Pepcidine from Merck & Co. was launched in Sweden. [ 3 ] In November 1993 Imodium Lingual ( loperamide ) from Janssen Pharmaceutica was released in Germany with Zydis technology.